




Instance: composition-en-3f214a4f5ac8e3dc74014e21089eb5bc
InstanceOf: CompositionUvEpi
Title: "Composition for vaxneuvance Package Leaflet"
Description:  "Composition for vaxneuvance Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp3f214a4f5ac8e3dc74014e21089eb5bc)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vaxneuvance"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Vaxneuvance is and what it is used for </li>
<li>What you need to know before you or your child receives Vaxneuvance</li>
<li>How Vaxneuvance is given</li>
<li>Possible side effects </li>
<li>How to store Vaxneuvance</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vaxneuvance is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vaxneuvance is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vaxneuvance is a pneumococcal vaccine given to:
* children from 6 weeks to less than 18 years of age to help protect against diseases such as
lung infection (pneumonia), inflammation of the coverings of the brain and spinal cord
(meningitis), a severe infection in the blood (bacteraemia) and ear infections (acute otitis
media),
* individuals 18 years of age and older to help protect against diseases such as lung infection
(pneumonia), inflammation of the coverings of the brain and spinal cord (meningitis) and a
severe infection in the blood (bacteraemia), caused by 15 types of bacteria called Streptococcus
pneumoniae or pneumococcus.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vaxneuvance"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vaxneuvance"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not receive Vaxneuvance if:
* you or your child is allergic to the active substances or to any of the ingredients of this vaccine
(listed in section 6), or to any vaccine that contains diphtheria toxoid.
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you or your child receives Vaxneuvance if:
* the immune system is weak (which means the body is less able to fight off infections) or if you
or your child is taking certain medicines that may make the immune system weak (for example,
immunosuppressants or steroids).
* you or your child has a high fever or severe infection. In these cases, the vaccination may have
to be postponed until you or your child has recovered. However, a mild fever or infection (for
example having a cold) itself is not a reason to delay vaccination.
* you or your child has any bleeding problems, bruises easily, or is taking medicines to prevent
blood clots.
If your child is an infant, also tell your doctor if your child was born prematurely (too early). 
As with any vaccine, Vaxneuvance may not fully protect all persons who are vaccinated.
Other medicines/vaccines and Vaxneuvance
Your child can be given Vaxneuvance at the same time as other routine childhood vaccines.
In adults, Vaxneuvance can be given at the same time as the flu (inactivated influenza) vaccine.
Tell your doctor, pharmacist, or nurse if:
* you or your child is taking, has recently taken, or might take any prescription medicines (for
example, immunosuppressants or steroids which may make the immune system weak) or any
medicines obtained without a prescription.
* you or your child has recently received or plan to receive any other vaccine.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor, pharmacist, or nurse for advice before you receive this vaccine.
Driving and using machines
Vaxneuvance has no or negligible influence on the ability to drive and use machines. However, some
of the effects mentioned under section 4  Possible side effects  may temporarily affect the ability to
drive or use machines.
Vaxneuvance contains sodium
This medicine contains less than 1 mmol sodium (23 milligrams) per dose, that is to say essentially
 sodium-free .</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vaxneuvance"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vaxneuvance"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tell your doctor, pharmacist, or nurse if you or your child has been given a pneumococcal vaccine
before.
Your doctor or nurse will give the vaccine into your arm muscle or into your child's arm or leg muscle.
Infants and children aged 6 weeks to less than 2 years<br />
Your child should receive an initial course of 2 injections of the vaccine followed by a booster dose.
* The first injection may be given as early as 6 weeks of age.
* A second injection is administered 2 months later.
* A third injection (booster) will be given between 11 through 15 months of age.
You will be told when your child should come back for each injection.
According to official recommendations in your country, an alternative schedule of 3 injections
followed by a booster dose may be used by your healthcare provider. Please speak to your doctor,
pharmacist, or nurse for more information.
Premature infants (born earlier than 37 weeks of pregnancy)
Your child should receive an initial course of 3 injections of the vaccine followed by a booster dose. 
* The first injection may be given as early as 6 weeks of age. 
* The second and third injections are given thereafter with an interval of 4 to 8 weeks between
doses. 
* A fourth injection (booster) will be given between 11 through 15 months of age.
Infants, children and adolescents starting the vaccination at 7 months of age or older
Infants 7 to less than 12 months of age should receive a total of 3 injections. The first two injections
will be given at least 1 month apart. The third injection (booster) will be given after 12 months of age
and at least 2 months after the second injection.
Children 12 months to less than 2 years of age should receive a total of 2 injections. The two
injections will be given at least 2 months apart. 
Children and adolescents 2 to less than 18 years of age should receive 1 injection.
Adults
Adults should receive 1 injection.
Special populations
One or more injections of Vaxneuvance may be given to individuals who have one or more underlying
conditions that increase their risk for pneumococcal disease (such as individuals with sickle cell
disease or living with human immunodeficiency virus [HIV] or recipients of a stem cell transplant). 
If you have any further questions on the use of Vaxneuvance, ask your doctor, pharmacist, or nurse.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all vaccines, Vaxneuvance can cause side effects, although not everybody gets them.
Get medical care right away if you or your child has symptoms of an allergic reaction, which may
include:
* Wheezing or trouble breathing
* Swelling of the face, lips, or tongue
* Hives
* Rash
The following side effects can be seen after the use of Vaxneuvance in infants, children and
adolescents:
Very common (may affect more than 1 in 10 people):
* Fever (temperature of 38  C or higher in those 6 weeks to less than 2 years of age)
* Irritability (in those 6 weeks to less than 2 years of age) 
* Drowsiness (in those 6 weeks to less than 2 years of age)
* Pain, redness or swelling at the injection site
* Decreased appetite (in those 6 weeks to less than 2 years of age)
* Hardness at the injection site (in those 6 weeks to less than 2 years of age)
* Muscle aches (in those 2 to less than 18 years of age)
* Feeling tired (in those 2 to less than 18 years of age)
* Headache (in those 2 to less than 18 years of age)
Common (may affect up to 1 in 10 people):
* Hardness at the injection site (in those 2 to less than 18 years of age)
* Hives
* Fever (temperature of 38  C or higher in those 2 to less than 18 years of age)
* Vomiting (in those 6 weeks to less than 2 years of age)
* Rash (in those 6 weeks to less than 2 years of age) 
* Irritability (in those 2 to less than 18 years of age)
* Drowsiness (in those 2 to less than 18 years of age)
* Decreased appetite (in those 2 to less than 18 years of age)
* Bruising at the injection site
* Nausea (in those 2 to less than 18 years of age)
Uncommon (may affect up to 1 in 100 people):
* Vomiting (in those 2 to less than 18 years of age)
Not known (cannot be estimated from the available data):
* Rash (in those 2 to less than 18 years of age) 
The following side effects can be seen after the use of Vaxneuvance in adults:
Very common (may affect more than 1 in 10 people):
* Pain, swelling, or redness at the injection site
* Feeling tired
* Muscle aches
* Headaches
* Joint pain (in those 18 to 49 years of age)
Common (may affect up to 1 in 10 people):
* Joint pain (in those 50 years of age and older)
* Nausea (in those 18 to 49 years of age)
* Fever (in those 18 to 49 years of age)
* Itchiness at the injection site
* Dizziness (in those 18 to 49 years of age)
* Chills (in those 18 to 49 years of age)
Uncommon (may affect up to 1 in 100 people):
* Fever (in those 50 years of age and older)
* Warmth at the injection site
* Bruising at the injection site
* Dizziness (in those 50 years of age and older)
* Nausea (in those 50 years of age and older)
* Vomiting
* Chills (in those 50 years of age and older)
* Rash
Rare (may affect up to 1 in 1,000 people):
* Allergic reaction such as hives, tongue swelling, flushing, and throat tightness
These side effects are generally mild and last a short time.
Reporting of side effects
If you or your child gets any side effects, talk to your doctor, pharmacist, or nurse. This includes any
possible side effects not listed in this leaflet. You can also report side effects directly via the national
reporting system listed in Appendix V. By reporting side effects you can help provide more
information on the safety of this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vaxneuvance"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vaxneuvance"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this vaccine out of the sight and reach of children.
Do not use this vaccine after the expiry date which is stated on the carton and syringe label after EXP.
The expiry date refers to the last day of that month.
Store in a refrigerator (2  C   8  C). Do not freeze. Keep the pre-filled syringe in the outer carton in
order to protect from light. 
Vaxneuvance should be administered as soon as possible after being removed from the refrigerator.
However, in circumstances where Vaxneuvance is temporarily held outside of refrigeration, the
vaccine is stable at temperatures up to 25  C for 48 hours.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Vaxneuvance contains
The active substances are:</p>
<ul>
<li>bacterial sugars from pneumococcus types 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F,
and 33F (2.0 micrograms of each type);</li>
<li>bacterial sugar from pneumococcus type 6B (4.0 micrograms).
Each bacterial sugar is linked to a carrier protein (CRM197). The bacterial sugars and the carrier protein
are not alive and do not cause disease.
One dose (0.5 mL) contains approximately 30 micrograms carrier protein, adsorbed on aluminium
phosphate (125 micrograms aluminium [Al3+]). Aluminium phosphate is included in the vaccine as an
adjuvant. Adjuvants are included to improve the immune responses of vaccines.
The other ingredients are sodium chloride (NaCl), L-histidine, polysorbate 20, and water for
injections.
What Vaxneuvance looks like and contents of the pack
Vaxneuvance is an opalescent suspension for injection, provided in a single-dose, pre-filled syringe
(0.5 mL). Vaxneuvance is available in pack sizes of 1 or 10, either without needles, with 1 separate
needle, or with 2 separate needles.
Vaxneuvance is also available in multipacks comprising 5 cartons, each containing 10 pre-filled
syringes without needles.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Merck Sharp &amp; Dohme B.V.
Waarderweg 2031 BN Haarlem
The Netherlands
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgi /Belgique/Belgien
MSD Belgium
T l/Tel: +32 (0) 27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370.5.2780.msd_lietuva@merck.com<pre><code>   ,
</code></pre>
<p>.: + 359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
T l/Tel: +32 (0) 27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o.
Tel.: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft.
Tel.: + 36.1.888.5hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: + 45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited.
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme O 
Tel.: +372 6144 msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no</p>
</li>
</ul>
<p>MSD  . . . . .
 : +30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Merck Sharp &amp; Dohme de Espa a, S.A.
Tel: +34 91 321 06 msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48 22 549 51 msdpolska@merck.com
France
MSD France
T l: +33 (0) 1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: +385 1 66 11 croatia_info@merck.com
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L
Tel: + 4021 529 29 msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386.1.520.4msd.slovenia@merck.com
 sland
Vistor hf.
S mi: + 354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r.* Tel: +421 2 58282dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 info@msd.fi</p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 : 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija 
United Kingdom (Northern Ireland)
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371.67364.msd_lv@merck.com
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last revised in {MM/YYYY}.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu.
&lt;------------------------------------------------------------------------------------------------------------------------&gt;
The following information is intended for healthcare professionals only:
Vaxneuvance must not be injected intravascularly.
* Immediately prior to use, hold the pre-filled syringe horizontally and shake vigorously to obtain
an opalescent suspension. Do not use the vaccine if it cannot be resuspended.
* Inspect the suspension visually for particulate matter and discolouration prior to administration.
Discard the vaccine if particulates are present and/or if it appears discoloured.
* Attach a needle with Luer lock connection by twisting in a clockwise direction until the needle
fits securely on the syringe.
* Inject immediately using the intramuscular (IM) route, preferably in the anterolateral aspect of
the thigh in infants or in the deltoid area of the upper arm in children and adults.
* Exercise care to avoid harm from an accidental needle stick.
No data are available for administration via the intradermal route.
Vaxneuvance must not be mixed with any other vaccines in the same syringe.
Vaxneuvance can be given concomitantly with other routine childhood vaccines.
Vaxneuvance can be administered concomitantly with seasonal quadrivalent influenza vaccine (split
virion, inactivated) in adults. 
Different injectable vaccines should always be administered at different injection sites.
Store in a refrigerator (2   8  ). Do not freeze.
Keep the pre-filled syringe in the outer carton in order to protect from light.
Vaxneuvance should be administered as soon as possible after being removed from the refrigerator.
In the event of temporary temperature excursions, stability data indicate that Vaxneuvance is stable at
temperatures up to 25    for 48 hours.
Any unused medicinal product or waste material should be disposed of in accordance with local
requirements.</p>         </div>"""      



Instance: composition-da-3f214a4f5ac8e3dc74014e21089eb5bc
InstanceOf: CompositionUvEpi
Title: "Composition for vaxneuvance Package Leaflet"
Description:  "Composition for vaxneuvance Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp3f214a4f5ac8e3dc74014e21089eb5bc)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vaxneuvance"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse 
2. Det skal du vide, før du eller dit barn får Vaxneuvance
3. Sådan får du eller dit barn Vaxneuvance
4. Bivirkninger 
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vaxneuvance is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vaxneuvance is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vaxneuvance er en pneumokokvaccine, som er med til at beskytte:</p>
<ul>
<li>
<p>børn i alderen 6 uger til under 18 år mod sygdomme såsom: lungeinfektion
(lungebetændelse), hjernehindebetændelse (meningitis, en infektion i hinderne omkring hjernen
og rygmarven), en alvorlig infektion i blodet (bakteriæmi) og mellemørebetændelse (akut otitis
media),</p>
</li>
<li>
<p>personer i alderen 18 år og derover mod sygdomme såsom: lungeinfektion (lungebetændelse),
hjernehindebetændelse (meningitis, en infektion i hinderne omkring hjernen og rygmarven) og
en alvorlig infektion i blodet (bakteriæmi), forårsaget af 15 bakterietyper kaldet Streptococcus
pneumoniae eller pneumokok. </p>
</li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vaxneuvance"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vaxneuvance"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du eller dit barn må ikke få Vaxneuvance</p>
<ul>
<li>
<p>hvis du eller dit barn er allergisk over for de aktive stoffer eller et af de øvrige indholdsstoffer i
vaccinen (angivet i punkt 6), eller over for vacciner, der indeholder difteritoksoid.
Advarsler og forsigtighedsregler
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du eller dit barn får Vaxneuvance hvis:</p>
</li>
<li>
<p>immunforsvaret er svagt (hvilket betyder, at kroppens evne til at bekæmpe infektioner er
forringet), eller hvis du eller dit barn tager visse lægemidler, der kan svække immunforsvaret
(f.eks. immundæmpende midler eller steroider).
37</p>
</li>
<li>
<p>du eller dit barn har høj feber eller en alvorlig infektion. I disse tilfælde skal vaccinationen
udskydes, indtil du eller dit barn er blevet rask. Let feber eller en infektion (f.eks. en forkølelse)
er dog ikke i sig selv en grund til at udskyde vaccinationen.
•
du eller dit barn har blødningsproblemer, let får blå mærker eller tager blodfortyndende medicin
for at forebygge blodpropper.
Hvis dit barn er et spædbarn, skal du også fortælle det til lægen, hvis dit barn er født for tidligt. 
Som for alle vacciner vil vaccination med Vaxneuvance ikke nødvendigvis yde fuld beskyttelse hos
alle personer, der bliver vaccineret. 
Brug af andre lægemidler/andre vacciner sammen med Vaxneuvance
Dit barn kan få Vaxneuvance samtidig med andre børnevacciner i det rutinemæssige
børnevaccinationsprogram.
Hos voksne kan Vaxneuvance gives samtidig med influenzavaccinen (inaktiveret influenza).
Fortæl lægen, apotekspersonalet eller sygeplejersken, hvis:</p>
</li>
<li>
<p>du eller dit barn tager, for nylig har taget eller planlægger at tage andre receptpligtige
lægemidler (f.eks. immundæmpende midler eller steroider, der kan svække immunforsvaret)
eller lægemidler, som ikke er købt på recept.</p>
</li>
<li>
<p>du eller dit barn for nylig har fået eller planlægger at få en hvilken som helst anden vaccine.
Graviditet og amning
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal
du spørge lægen, apotekspersonalet eller sygeplejersken til råds, før du får denne vaccine.
Trafik- og arbejdssikkerhed
Vaxneuvance påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene
maskiner. Nogle af de bivirkninger, der er nævnt under punkt 4 "Bivirkninger", kan dog midlertidigt
påvirke evnen til at føre motorkøretøj eller betjene maskiner.
Vaxneuvance indeholder natrium
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, dvs. det er i det
væsentlige natriumfrit.</p>
</li>
</ul>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vaxneuvance"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vaxneuvance"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Fortæl lægen, apotekspersonalet eller sygeplejersken, hvis du eller dit barn har fået en
pneumokokvaccine før.
Lægen eller sygeplejersken vil give vaccinen i musklerne i din arm eller i musklerne i armen eller
benet hos dit barn.
Spædbørn og børn i alderen 6 uger til under 2 år
Dit barn vil få en indledende serie på 2 indsprøjtninger af vaccinen efterfulgt af en boosterdosis.</p>
<ul>
<li>
<p>Den første indsprøjtning kan gives så tidligt som i 6-ugers alderen.</p>
</li>
<li>
<p>En anden indsprøjtning gives 2 måneder senere.</p>
</li>
<li>
<p>En tredje indsprøjtning (boosterdosis) gives i alderen fra 11 til 15 måneder.
Du vil få oplyst, hvornår dit barn skal komme og få de næste vaccinationer.
Sundhedsvæsenet i Danmark kan anvende en anden plan med 3 indsprøjtninger efterfulgt af en
boosterdosis i henhold til de officielle anbefalinger. Du kan tale med din læge, apotekspersonalet eller
sygeplejersken og få yderligere oplysninger.
38
For tidligt fødte spædbørn (født før 37. svangerskabsuge)
Dit barn vil få en indledende serie på 3 indsprøjtninger af vaccinen efterfulgt af en boosterdosis. </p>
</li>
<li>
<p>Det første indsprøjtning kan gives så tidligt som i 6-ugers alderen.</p>
</li>
<li>
<p>Den anden og tredje indsprøjtning gives derefter med 4 til 8 ugers mellemrum mellem doserne. </p>
</li>
<li>
<p>En fjerde indsprøjtning (boosterdosis) gives i alderen fra 11 til 15 måneder.
Spædbørn, børn og unge, der påbegynder vaccination i alderen 7 måneder eller derover
Spædbørn i alderen 7 måneder til under 12 måneder skal have 3 indsprøjtninger i alt. De første
2 indsprøjtninger skal gives med mindst 1 måneds mellemrum. Den tredje indsprøjtning (boosterdosis)
gives efter 12-måneders alderen og mindst 2 måneder efter den anden indsprøjtning.
Børn i alderen 12 måneder til under 2 år skal have 2 indsprøjtninger i alt. De 2 indsprøjtninger skal
gives med mindst 2 måneders mellemrum. 
Børn og unge i alderen 2 år til under 18 år skal have 1 indsprøjtning.
Voksne
Voksne skal have 1 indsprøjtning.
Særlige populationer
En eller flere indsprøjtninger med Vaxneuvance kan gives til personer, der har en eller flere
underliggende sygdomme, som øger risikoen for pneumokoksygdom (såsom personer med
seglcellesygdom eller humant immundefektvirus (hiv)-infektion eller personer, som har gennemgået
en stamcelletransplantation).
Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om.</p>
</li>
</ul>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vaxneuvance kan som alle andre vacciner give bivirkninger, men ikke alle får bivirkninger.
Søg straks lægehjælp, hvis du eller dit barn har symptomer på en allergisk reaktion, som kan inkludere:</p>
<ul>
<li>
<p>Hiven efter vejret eller vejrtrækningsproblemer</p>
</li>
<li>
<p>Hævelse af ansigt, læber eller tunge</p>
</li>
<li>
<p>Nældefeber</p>
</li>
<li>
<p>Udslæt.
Følgende bivirkninger kan ses efter anvendelse af Vaxneuvance hos spædbørn, børn og unge:
Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer):</p>
</li>
<li>
<p>Feber (temperatur på 38 °C eller derover hos personer i alderen 6 uger til under 2 år)</p>
</li>
<li>
<p>Irritabilitet (hos personer i alderen 6 uger til under 2 år)</p>
</li>
<li>
<p>Døsighed (hos personer i alderen 6 uger til under 2 år)</p>
</li>
<li>
<p>Smerter, rødme eller hævelser på injektionsstedet</p>
</li>
<li>
<p>Nedsat appetit (hos personer i alderen 6 uger til under 2 år)</p>
</li>
<li>
<p>Hårdhed på injektionsstedet (hos personer i alderen 6 uger til under 2 år)</p>
</li>
<li>
<p>Muskelsmerter (hos personer i alderen 2 år til under 18 år)</p>
</li>
<li>
<p>Træthedsfølelse (hos personer i alderen 2 år til under 18 år)</p>
</li>
<li>
<p>Hovedpine (hos personer i alderen 2 år til under 18 år).
Almindelig (kan forekomme hos op til 1 ud af 10 personer):</p>
</li>
<li>
<p>Hårdhed på injektionsstedet (hos personer i alderen 2 år til under 18 år)</p>
</li>
<li>
<p>Nældefeber</p>
</li>
<li>
<p>Feber (temperatur på 38 °C eller derover hos personer i alderen 2 år til under 18 år)</p>
</li>
<li>
<p>Opkastning (hos personer i alderen 6 uger til under 2 år)</p>
</li>
<li>
<p>Udslæt (hos personer i alderen 6 uger til under 2 år)
39</p>
</li>
<li>
<p>Irritabilitet (hos personer i alderen 2 år til under 18 år)</p>
</li>
<li>
<p>Døsighed (hos personer i alderen 2 år til under 18 år)</p>
</li>
<li>
<p>Nedsat appetit (hos personer i alderen 2 år til under 18 år)</p>
</li>
<li>
<p>Blå mærker på injektionsstedet</p>
</li>
<li>
<p>Kvalme (hos personer i alderen 2 år til under 18 år).
Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer):</p>
</li>
<li>
<p>Opkastning (hos personer i alderen 2 år til under 18 år).
Ikke kendt (kan ikke vurderes ud fra tilgængelige data):</p>
</li>
<li>
<p>Udslæt (hos personer i alderen 2 år til under 18 år). 
Følgende bivirkninger kan ses efter anvendelse af Vaxneuvance hos voksne:
Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer):</p>
</li>
<li>
<p>Smerter, hævelse eller rødme på injektionsstedet</p>
</li>
<li>
<p>Træthedsfølelse</p>
</li>
<li>
<p>Muskelsmerter</p>
</li>
<li>
<p>Hovedpine</p>
</li>
<li>
<p>Ledsmerter (hos personer i alderen 18 til 49 år).
Almindelig (kan forekomme hos op til 1 ud af 10 personer):</p>
</li>
<li>
<p>Ledsmerter (hos personer i alderen 50 år og derover)</p>
</li>
<li>
<p>Kvalme (hos personer i alderen 18 til 49 år)</p>
</li>
<li>
<p>Feber (hos personer i alderen 18 til 49 år)</p>
</li>
<li>
<p>Kløe på injektionsstedet</p>
</li>
<li>
<p>Svimmelhed (hos personer i alderen 18 til 49 år)</p>
</li>
<li>
<p>Kulderystelser (hos personer i alderen 18 til 49 år).
Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer):</p>
</li>
<li>
<p>Feber (hos personer i alderen 50 år og derover)</p>
</li>
<li>
<p>Varme på injektionsstedet</p>
</li>
<li>
<p>Blå mærker på injektionsstedet</p>
</li>
<li>
<p>Svimmelhed (hos personer i alderen 50 år og derover)</p>
</li>
<li>
<p>Kvalme (hos personer i alderen 50 år og derover)</p>
</li>
<li>
<p>Opkastning</p>
</li>
<li>
<p>Kulderystelser (hos personer i alderen 50 år og derover)</p>
</li>
<li>
<p>Udslæt.
Sjælden (kan forekomme hos op til 1 ud af 1.000 personer):</p>
</li>
<li>
<p>Allergiske reaktioner såsom nældefeber, hævet tunge, ansigtsrødme og en følelse af
sammensnøring i halsen.
Disse bivirkninger er generelt lette og kortvarige.
Indberetning af bivirkninger
Hvis du eller dit barn oplever bivirkninger, bør du tale med lægen, apotekspersonalet eller
sygeplejersken. Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel.
Du eller dine pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det
nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe
med at fremskaffe mere information om sikkerheden af dette lægemiddel.
40</p>
</li>
</ul>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vaxneuvance"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vaxneuvance"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar vaccinen utilgængeligt for børn.
Brug ikke vaccinen efter den udløbsdato, der står på kartonen og injektionssprøjtens etiket efter EXP.
Udløbsdatoen er den sidste dag i den nævnte måned.
Opbevares i køleskab (2 C - 8 C). Må ikke nedfryses. Opbevar den fyldte injektionssprøjte i den
ydre karton for at beskytte mod lys.
Vaxneuvance skal administreres så hurtigt som muligt, efter det er taget ud af køleskabet. I tilfælde
hvor Vaxneuvance opbevares midlertidigt uden for køleskabet, er vaccinen dog stabil ved temperaturer
op til 25 C i 48 timer.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vaxneuvance indeholder:
Aktive stoffer:</p>
<ul>
<li>bakterielle sukkerstoffer (bakteriepolysaccharider) fra pneumokoktyperne 1, 3, 4, 5, 6A, 7F, 9V,
14, 18C, 19A, 19F, 22F, 23F og 33F (2,0 mikrogram af hver type)</li>
<li>bakterielt sukkerstof fra pneumokoktype 6B (4,0 mikrogram).
Hvert bakterielt sukkerstof er bundet til et bærerprotein (CRM197). De bakterielle sukkerstoffer og
bærerproteinet er ikke levende og forårsager ikke sygdom.
En dosis (0,5 ml) indeholder cirka 30 mikrogram bærerprotein adsorberet på aluminiumphosphat
(125 mikrogram aluminium [Al3+]). Aluminiumphosphat er tilsat vaccinen som adjuvans. Adjuvanser
tilsættes for at forbedre vacciners immunrespons.
Øvrige indholdsstoffer: natriumchlorid (NaCl), L-histidin, polysorbat 20 og vand til injektionsvæsker.
Udseende og pakningsstørrelser
Vaxneuvance er en opaliserende injektionsvæske, suspension, leveret i en fyldt enkeltdosis-
injektionssprøjte (0,5 ml). Vaxneuvance fås i pakningsstørrelser på 1 eller 10 stk., enten uden kanyler,
med 1 separat kanyle eller med 2 separate kanyler. 
Vaxneuvance fås også som en multipakning med 5 kartoner, der hver indeholder 10 fyldte
injektionssprøjter uden kanyler.
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen og fremstiller
Merck Sharp &amp; Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Holland
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
MSD Belgium
Tél/Tel: +32 (0) 27766211
dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370.5.2780.247
msd_lietuva@merck.com
41
България
Мерк Шарп и Доум България ЕООД,
тел.: + 359 2 819 3737
info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
Tél/Tel: +32 (0) 27766211
dpoc_belux@merck.com
Česká republika
Merck Sharp &amp; Dohme s.r.o.
Tel.: +420 233 010 111
dpoc_czechslovak@merck.com
Magyarország
MSD Pharma Hungary Kft.
Tel.: + 36.1.888.5300
hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf.: + 45 4482 4000
dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited.
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme OÜ
Tel.: +372 6144 200
msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no
Ελλάδα
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
dpoc_greece@merck.com
Österreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@merck.com
España
Merck Sharp &amp; Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48 22 549 51 00
msdpolska@merck.com
Frankrig
MSD France
Tél: +33 (0) 1 80 46 40 40
Portugal
Merck Sharp &amp; Dohme, Lda
Tel:+351 21 4465700
inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: +385 1 66 11 333
croatia_info@merck.com
România
Merck Sharp &amp; Dohme Romania S.R.L
Tel: + 4021 529 29 00
msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386.1.520.4201
msd.slovenia@merck.com
Ísland
Vistor hf.
Sími: + 354 535 7000
Slovenská republika
Merck Sharp &amp; Dohme, s. r.* Tel: +421 2 58282010
dpoc_czechslovak@merck.com
42
Italia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi
Κύπρος
Merck Sharp &amp; Dohme Cyprus Limited
Τηλ: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371.67364.224
msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfoNI@msd.com
Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}.
Andre informationskilder
Du kan finde yderligere oplysninger om dette lægemiddel Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu</li>
</ul>
<hr />
<p>Nedenstående oplysninger er kun til sundhedspersoner:
Vaxneuvance må ikke injiceres intravaskulært.</p>
<ul>
<li>
<p>Umiddelbart før brug skal den fyldte injektionssprøjte holdes vandret og omrystes grundigt for
at opnå en opaliserende suspension. Brug ikke vaccinen, hvis den ikke kan resuspenderes.</p>
</li>
<li>
<p>Inspicer suspensionen visuelt for partikler og misfarvning inden administration. Kasser
vaccinen, hvis der er partikler til stede, og/eller hvis den fremstår som misfarvet.</p>
</li>
<li>
<p>Fastgør en kanyle med Luer-lock-samling ved at dreje med uret, indtil kanylen sidder godt og
sikkert fast i injektionssprøjten.</p>
</li>
<li>
<p>Injicer straks intramuskulært (i.m.), helst i den anterolaterale side af låret hos spædbørn eller i
deltamusklen i overarmen hos børn og voksne.</p>
</li>
<li>
<p>Udvis forsigtighed for at undgå utilsigtede kanylestik.
Der foreligger ingen data vedrørende intradermal administration.
Vaxneuvance må ikke blandes med andre vacciner i den samme injektionssprøjte.
Vaxneuvance kan gives samtidig med andre børnevacciner i det rutinemæssige
børnevaccinationsprogram.
Vaxneuvance kan administreres samtidig med sæsonbestemt tetravalent influenzavaccine (split virion,
inaktiveret) hos voksne. 
Forskellige injicerbare vacciner skal altid administreres på forskellige injektionssteder.
Opbevares i køleskab (2 °C - 8 °C). Må ikke nedfryses.
Opbevar den fyldte injektionssprøjte i den ydre karton for at beskytte mod lys.
Vaxneuvance skal administreres så hurtigt som muligt, efter det er taget ud af køleskabet.
43
I tilfælde af midlertidige temperaturudsving indikerer stabilitetsdata, at Vaxneuvance er stabilt ved
temperaturer op til 25 °C i 48 timer.
Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer.</p>
</li>
</ul>         </div>"""      





                    
Instance: bundlepackageleaflet-en-3f214a4f5ac8e3dc74014e21089eb5bc
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vaxneuvance Package Leaflet for language en"
Description: "ePI document Bundle for vaxneuvance Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-3f214a4f5ac8e3dc74014e21089eb5bc"
* entry[0].resource = composition-en-3f214a4f5ac8e3dc74014e21089eb5bc

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3f214a4f5ac8e3dc74014e21089eb5bc"
* entry[=].resource = mp3f214a4f5ac8e3dc74014e21089eb5bc
                            
                    
Instance: bundlepackageleaflet-da-3f214a4f5ac8e3dc74014e21089eb5bc
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vaxneuvance Package Leaflet for language da"
Description: "ePI document Bundle for vaxneuvance Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-3f214a4f5ac8e3dc74014e21089eb5bc"
* entry[0].resource = composition-da-3f214a4f5ac8e3dc74014e21089eb5bc

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3f214a4f5ac8e3dc74014e21089eb5bc"
* entry[=].resource = mp3f214a4f5ac8e3dc74014e21089eb5bc
                            
                    



Instance: mp3f214a4f5ac8e3dc74014e21089eb5bc
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Vaxneuvance suspension for injection in pre-filled syringe"
Description: "Vaxneuvance suspension for injection in pre-filled syringe"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1591/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Vaxneuvance suspension for injection in pre-filled syringe"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 3f214a4f5ac8e3dc74014e21089eb5bcListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "vaxneuvance"

* status = #current
* mode = #working

* title = "List of all ePIs associated with vaxneuvance"

* subject = Reference(mp3f214a4f5ac8e3dc74014e21089eb5bc)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#vaxneuvance "vaxneuvance"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-3f214a4f5ac8e3dc74014e21089eb5bc) // vaxneuvance en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-3f214a4f5ac8e3dc74014e21089eb5bc) // vaxneuvance da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-3f214a4f5ac8e3dc74014e21089eb5bc
InstanceOf: List

* insert 3f214a4f5ac8e3dc74014e21089eb5bcListRuleset
    